Part 1
The MHRA perspective
The regulator's view of synthetic data in medicines development and evidence generation.
Session materialsSlides and notes for this part will be added here.
Part 1
The regulator's view of synthetic data in medicines development and evidence generation.
Part 2
A response from Regulatory Scientific and Health Solutions (RSS).
Step 6 of the workflow: method, settings, checks and limitations.
Near-copies, membership inference and differential privacy.